Compass Therapeutics, Inc.
CMPX
Rank in Stocks
#17922
Compass Therapeutics, Inc. is a biopharmaceutical firm focused on developing... Compass Therapeutics, Inc. is a biopharmaceutical firm focused on developing cancer treatments, with several therapeutic candidates currently in clinical trials. The company's work involves creating antibody-based medicines designed to address a variety of human health conditions. Among its leading clinical-stage programs are CTX-009, an experimental bispecific antibody engineered to inhibit the Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, both of which are crucial for the growth of new blood vessels and tumor vascularization. Another significant compound is CTX-471, an IgG4 monoclonal antibody that functions as an activator of CD137. Furthermore, their developmental pipeline features CTX-8371, a bispecific inhibitor that targets both PD-1 and PD-L1. The company was established in 2014 and operates from its headquarters in Boston, Massachusetts.
Share Price
$0.8369
Last synced: 2026-11-09
Market Cap
$150.72M
Change (1 day)
10.29%
Change (1 year)
-81.92%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Compass Therapeutics, Inc. (CMPX)
Category
Healthcare
EPS for Compass Therapeutics, Inc. (CMPX)
EPS as of June 2026 TTM: $-0.41
According to Compass Therapeutics, Inc.'s latest financial reports, its current EPS (TTM) is $-0.41. At the end of 2025 the company had an EPS of $-0.42, a decrease compared to its 2024 EPS of $-0.36.
EPS history for Compass Therapeutics, Inc. from 2019 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.41 | -2.38% |
| 2025 | $-0.42 | 16.67% |
| 2024 | $-0.36 | 9.09% |
| 2023 | $-0.33 | -5.71% |
| 2022 | $-0.35 | -73.28% |
| 2021 | $-1.31 | 151.92% |
| 2020 | $-0.52 | -93.21% |
| 2019 | $-7.66 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -3,919.51% |
US
|
|
| $-7.07 | 1,624.39% |
US
|
|
| $-5.29 | 1,190.24% |
AU
|
|
| $12.88 | -3,241.49% |
BE
|
|
| $21.56 | -5,358.54% |
NL
|
Questions about Compass Therapeutics, Inc.'s earnings per share (EPS)
What is Compass Therapeutics, Inc.'s earnings per share (EPS)?
Compass Therapeutics, Inc.'s earnings per share (EPS) over the last twelve months is $-0.41, as of Jun 2026.
What was Compass Therapeutics, Inc.'s earnings per share (EPS) in 2025?
In 2025, Compass Therapeutics, Inc.'s earnings per share (EPS) was $-0.42, compared with $-0.36 in 2024.
How has Compass Therapeutics, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Compass Therapeutics, Inc.'s earnings per share (EPS) was highest in 2023 ($-0.33) and lowest in 2021 ($-1.31).
How does Compass Therapeutics, Inc.'s earnings per share (EPS) compare with similar companies?
Compass Therapeutics, Inc.'s earnings per share (EPS) ($-0.41) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.